Ravish A

Novo Nordisk: Set to Conquer the Insulin Market - Barron's

Novo Nordisk is in the right market: diabetes.

However, I think its growth needs to also come from other sources inorder to sustain it's current level of growth..i would still buy NovoNordisk but I feel it's growth rate may slow mainly because diabetes can be managed well with prevention and the more people understand the disease, there is less need for insulin.